RESUMEN
OBJECTIVES: To study the effect of two protamine-dosing strategies on activated clotting time (ACT) and thromboelastography (TEG). BACKGROUND: Protamine dosage based on neutralizing heparin present in the combined estimated blood volumes (EBVs) of the patient and cardiopulmonary bypass (CPB) pump may result in excess protamine and contributes toward a coagulopathy that can be detected by ACT and TEG in pediatric patients. METHODS: A total of 100 pediatric patients 1 month to ≤5 years of age undergoing CPB were included in this retrospective before/after design study. Combined-EBV group consisted of 50 consecutive patients whose protamine dose was calculated to neutralize heparin in the combined EBVs of the patient and the pump. Pt-EBV group consisted of the next 50 consecutive patients whose protamine dose was calculated to neutralize heparin in the patient's EBV. RESULTS: Baseline and postprotamine ACTs were similar between groups. Postprotamine heparin assay (Hepcon) showed the absence of residual heparin in both groups. Postprotamine kaolin-heparinase TEG showed that R was prolonged by 7.5 min in the Combined-EBV group compared with the Pt-EBV group (mean R of 20.17 vs. 12.4 min, respectively, P < 0.001). Increasing doses of protamine were associated with a corresponding, but nonlinear increase in R. There was no significant difference in the changes for K, alpha, and MA between the groups. CONCLUSION: Automated protamine titration with a protamine dosage based on Pt-EBV can adequately neutralize heparin as assessed by ACT while minimizing prolonging clot initiation time as measured by TEG.
Asunto(s)
Puente Cardiopulmonar , Antagonistas de Heparina/administración & dosificación , Antagonistas de Heparina/farmacología , Protaminas/administración & dosificación , Protaminas/farmacología , Tromboelastografía/efectos de los fármacos , Tiempo de Coagulación de la Sangre Total , Anticoagulantes/efectos adversos , Anticoagulantes/uso terapéutico , Procedimientos Quirúrgicos Cardíacos , Manejo de Caso , Preescolar , Relación Dosis-Respuesta a Droga , Femenino , Heparina/efectos adversos , Heparina/uso terapéutico , Humanos , Lactante , Recién Nacido , Masculino , Análisis de RegresiónRESUMEN
Hereditary spherocytosis (HS) is a genetic, frequently familial hemolytic blood disease that presents with varying degrees of hemolytic anemia, splenomegaly, and jaundice.The disease arises as a result of defects in any of a number of proteins responsible for maintaining the shape and flexibility of the red blood cell, resulting in an osmotically fragile and characteristically spherical red blood cell. Theoretically, cardiopulmonary bypass can exacerbate hemolysis and subsequent renal dysfunction.There are few reports of open heart surgery for patients with HS and none for orthotopic heart transplantation.We report a 6-year-old boy with HS who underwent orthotopic heart transplantation.
Asunto(s)
Trasplante de Corazón , Esferocitosis Hereditaria/complicaciones , Niño , Pruebas Hematológicas , Humanos , Masculino , Esferocitosis Hereditaria/sangreRESUMEN
Low serum cholesterol has long been associated with hemorrhagic stroke even though the mechanism for this association has yet to be elucidated. The association of low serum cholesterol with hemorrhagic stroke has been described thus far only in adult studies. There have been no reports of this association in children. We present a case of a hemorrhagic stroke that occurred in a 6-year-old, severely malnourished child who had just received augmentation of cardiac output with a pulsatile left ventricular assist device.
Asunto(s)
Hemorragia Cerebral/diagnóstico , Hemorragia Cerebral/terapia , Colesterol/sangre , Corazón Auxiliar , Gasto Cardíaco , Cardiomiopatía Dilatada/complicaciones , Hemorragia Cerebral/complicaciones , Hemorragia Cerebral/tratamiento farmacológico , Niño , Trastornos de la Nutrición del Niño/complicaciones , Enfermedad Crónica , Femenino , Insuficiencia Cardíaca/complicaciones , Humanos , Apoyo Nutricional , Tomógrafos Computarizados por Rayos XRESUMEN
Modern technologic advances in medicine have allowed commonly used machines to perform safely with very low risk and a high degree of success. To detect or prevent potential malfunctions, professionals routinely perform pre-use checks for equipment such as anesthesia machines and cardiopulmonary bypass (CPB) machines. These machine checklists are not only critical for a safe operation but also have large impacts on outcomes. For example, when malfunctions are encountered that could have potential negative ramifications or adverse outcomes, multi-approach strategies should be used to identify rectifiable causes and find solutions that are practical. This information can be used to promulgate safe practice guidelines. This case report identifies a machine-based contributing factor to precipitous hypoxia on initiation of bypass in one of our patients. After a detailed approach to identify preventable root causes, we made simple additions to our pre-bypass checklist and recommend these changes to other institutions.
Asunto(s)
Puente Cardiopulmonar/instrumentación , Puente Cardiopulmonar/normas , Falla de Equipo , Complicaciones Intraoperatorias , Administración de la Seguridad , Humanos , Lactante , Garantía de la Calidad de Atención de SaludRESUMEN
Lawnmowers are one of the most frequent causes of mutilating injuries to children. The majority of accidents are caused by negligence of the operator. Most injuries of this type are caused by direct contact with the spinning blade and, less frequently, by projectiles propelled by the blade. Such projectiles usually produce bruises, but can penetrate skin and soft tissues. This report presents a 6-year-old child who suffered a small, outwardly insignificant puncture wound of the chest from a lawnmower-propelled projectile who presented with fever and chest pain the following day. The diagnostic work up and treatment of this deceptively life-threatening wound are discussed.
Asunto(s)
Cuerpos Extraños/fisiopatología , Vena Cava Superior/lesiones , Niño , Cuerpos Extraños/cirugía , Humanos , Masculino , Ultrasonografía , Vena Cava Superior/diagnóstico por imagenAsunto(s)
Trastornos de la Coagulación Sanguínea/inducido químicamente , Trastornos de la Coagulación Sanguínea/enzimología , Factor VII/metabolismo , Ácidos Pipecólicos/efectos adversos , Tromboelastografía , Arginina/análogos & derivados , Trastornos de la Coagulación Sanguínea/prevención & control , Niño , Femenino , Humanos , Sulfonamidas , Tromboelastografía/métodos , Factores de TiempoRESUMEN
A 10-year-old boy who was receiving support from a ventricular assist device (VAD) experienced heparin-induced thrombocytopenia that was successfully treated with high-dose argatroban infusion to attain therapeutic activated partial thromboplastin time in spite of high serum argatroban levels. This case also highlights bolus argatroban dosing for VAD change in the setting of persistent ventricular fibrillation.
Asunto(s)
Selección de Profesión , Hepacivirus , Hepatitis C Crónica/transmisión , Transmisión de Enfermedad Infecciosa de Paciente a Profesional , Internado y Residencia , HumanosRESUMEN
BACKGROUND: Cerebrovascular events (CVEs) are common among children supported with the Berlin EXCOR (Berlin Heart GmbH, Berlin, Germany) ventricular assist device (VAD). Given the high incidence of CVEs associated with this device, we sought to describe our institutional experience in incrementally reducing CVEs in children supported with the Berlin EXCOR VAD. METHODS: We collected pertinent data on 39 consecutive patients who underwent Berlin EXCOR VAD implantation at a single center. Frequency of CVEs was described in risk per implantation, per day, and in reference to the time of therapeutic anticoagulation. Risk factors were analyzed for association with CVEs. RESULTS: Of the initial 39 Berlin EXCOR VAD implantations, 16 CVEs occurred in 12 patients. The incidence of CVEs decreased with institutional experience per patient (R(2) = 0.6909, p = 0.007) and per patient-day (R(2) = 0.8051, p = 0.002). CVEs occurred more frequently before therapeutic anticoagulation targets were achieved (4.1%/day) compared with after therapeutic anticoagulation targets were achieved (0.9%/day; p = 0.044). CONCLUSIONS: Incidence of CVEs decreased with institutional experience. The risk of CVE is highest in the immediate postoperative period before therapeutic anticoagulation is achieved. Further studies are warranted in pediatric patients supported with the Berlin EXCOR VAD to confirm our findings in a larger cohort.
Asunto(s)
Corazón Auxiliar/efectos adversos , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/etiología , Niño , Preescolar , Humanos , Incidencia , Diseño de Prótesis , Estudios Retrospectivos , Accidente Cerebrovascular/prevención & controlRESUMEN
OBJECTIVE: Many centers are able to emergently deploy extracorporeal membrane oxygenation (ECMO) as support in children with refractory hemodynamic instability, but may be limited in their ability to provide prolonged circulatory support or cardiac transplantation. Such patients may require interhospital transport while on ECMO (cardiac mobile [CM]-ECMO) for additional hemodynamic support or therapy. There are only three centers in the United States that routinely perform CM-ECMO. Our center has a 20-year experience in carrying out such transports. The purpose of this study was twofold: (1) to review our experience with pediatric cardiac patients undergoing CM-ECMO and (2) identify risk factors for a composite outcome (defined as either cardiac transplantation or death) among children undergoing CM-ECMO. DESIGN: Retrospective case series. SETTING: Cardiovascular intensive care and pediatric transport system. PATIENTS: Children (n = 37) from 0-18 years undergoing CM-ECMO transports (n = 38) between January 1990 and September 2005. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 38 CM-ECMO transports were performed for congenital heart disease (n = 22), cardiomyopathy (n = 11), and sepsis with myocardial dysfunction (n = 4). There were 18 survivors to hospital discharge. Twenty-two patients were transported a distance of more than 300 miles from our institution. Ten patients were previously cannulated and on ECMO prior to transport. Thirty-five patients were transported by air and two by ground. Six patients underwent cardiac transplantation, all of whom survived to discharge. After adjusting for other covariates post-CM-ECMO renal support was the only variable associated with the composite outcome of death/need for cardiac transplant (odds ratio = 13.2; 95% confidence interval, 1.60--108.90; P = 0.003). There were two minor complications (equipment failure/dysfunction) and no major complications or deaths during transport. CONCLUSIONS: Air and ground CM-ECMO transport of pediatric patients with refractory myocardial dysfunction is safe and effective. In our study cohort, the need for post-CM-ECMO renal support was associated with the composite outcome of death/need for cardiac transplant.
Asunto(s)
Oxigenación por Membrana Extracorpórea , Cardiopatías/terapia , Hemodinámica , Transferencia de Pacientes , Transporte de Pacientes , Adolescente , Ambulancias Aéreas , Ambulancias , Arkansas , Niño , Preescolar , Diseño de Equipo , Oxigenación por Membrana Extracorpórea/efectos adversos , Oxigenación por Membrana Extracorpórea/instrumentación , Oxigenación por Membrana Extracorpórea/mortalidad , Femenino , Cardiopatías/mortalidad , Cardiopatías/fisiopatología , Trasplante de Corazón , Mortalidad Hospitalaria , Hospitales Pediátricos , Humanos , Lactante , Recién Nacido , Modelos Logísticos , Masculino , Oportunidad Relativa , Alta del Paciente , Diálisis Renal/efectos adversos , Diálisis Renal/mortalidad , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo , Resultado del TratamientoRESUMEN
For children requiring mechanical circulatory support as a bridge to cardiac transplantation in North America, options previously were limited to extracorporeal membrane oxygenation (ECMO) or centrifugal pump ventricular assist, both of which were suitable for only very short term application and were associated with significant complications and limitations. The Berlin Heart EXCOR ventricular assist device (VAD) was recently introduced into practice in North America to address this deficiency. We report a preliminary single center experience with the EXCOR in 17 children, 13 who received only a left-sided pump and four who required biventricular support. Before EXCOR placement, six patients were on ECMO, and one was on a centrifugal VAD. Eleven children were bridged to transplantation, one was bridged to recovery, and one remains on support. Three children died during support and one died after explantation. There was one late death nearly 2 years after transplant. Complications included stroke in seven patients, two of which were ultimately fatal. Five patients required re-operations for bleeding or evacuation of hematoma. Despite a disappointing rate of neurologic morbidity, our preliminary experience with the EXCOR has been very encouraging.